HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Triptan Switches Offer Hope For Australia’s OTC Market

Executive Summary

Switch expert Natalie Gauld says recent triptan switch recommendations signal a turnaround for Australia's OTC market.

You may also be interested in...



Australia Introduces ‘Appendix M’ Criteria To Facilitate Innovative Switches

Australia's Therapeutic Goods Administration has introduced a set of criteria introducing additional controls for medicines rescheduled from ‘Schedule 4’ (prescription-only) to ‘Schedule 3’ (non-prescription, pharmacist-only) status, intended to facilitate more innovative prescription-to-OTC switches in the future.

Post-Switch Market Exclusivity Benefits Everyone, Insists Global Switch Expert

Three- to five-year market exclusivity periods for switched products would not only incentivize consumer healthcare firms but also enable pre- and post-switch data to be generated more easily, thus improving the quality of switch applications, explains global switch expert Dr Natalie Gauld in the final part of our exclusive interview. 

German Switch Committee Meets: Sumatriptan Goes Again, Antihistamine Reverse-Switch Rejected, For Now

Germany’s Expert Committee for Prescription recommends prescription-to-OTC reclassifications of sumatriptan for migraines and liquid ibuprofen, but rejects an OTC switch for ketoprofen and the reverse-switch of sedative antihistamines for over 65s.

Related Content

Topics

UsernamePublicRestriction

Register

WI964834

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel